27.11.2023 - NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophreniaWATERTOWN, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) - Neumora Therapeutics, Inc. (Neumora), a . Seite 1
30.10.2023 - WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) - Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will participate in two investor .